Answers are grounded in this paper and cite their sources.
In vitro assessment predicts interaction risk between verapamil and fenoterol, implying caution during coadministration.
An in vitro OCT1 inhibition assay using fenoterol as probe substrate was validated and identified that verapamil may pose a clinically relevant interaction risk, predicting a minimum 2-fold increase in fenoterol exposure. This highlights the need for caution when coadministrating verapamil with fenoterol and supports incorporating OCT1 inhibition profiling into preclinical evaluation of new drug entities to better inform clinical development and ensure patient safety.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: